Agilent Technologies has announced the launch of the Agilent S540MD Slide Scanner System, a whole-slide imaging (WSI) digital scanner, available for sale in key European markets.
The launch – a collaboration with Hamamatsu – reflects Agilent’s continued investment in digital pathology, expanding its portfolio to meet the growing demand for high-throughput solutions in clinical laboratories.
Pathology laboratories worldwide require robust, high-speed scanning solutions that integrate seamlessly into existing workflows, as reliance on traditional glass-slide workflows alone can slow turnaround times and overall output.
Engineered for speed and scalability, the Agilent S540MD offers capacity for up to 540 slides, continuous loading, and standard rack compatibility. The scanner features automated scanning modes and AI-assisted tissue detection, enabling high-volume pathology laboratories to digitise glass slides efficiently and to implement digital and AI-driven workflows. The new scanner is the Agilent-branded version of the Hamamatsu NanoZoomer S540MD Slide Scanner System.
With the introduction of the Agilent S540MD scanner, Agilent enhances its capabilities in digital pathology, enriching its offering from staining to AI decision support and providing laboratories with increased flexibility to select solutions that align with their specific requirements.
Nina Green, Vice President and General Manager of the Clinical Diagnostics Division at Agilent, said: “The introduction of the Agilent S540MD Slide Scanner System marks an important advancement in our commitment to equip pathology laboratories with advanced digital technologies. This initiative facilitates the acceleration of diagnostic workflows and supports improved patient outcomes. Our partnership with Hamamatsu demonstrates Agilent’s ongoing dedication to delivering integrated, fully interoperable solutions to address the evolving needs of clinical laboratories.”
The Agilent S540MD scanner will initially be available as IVD in Germany, France, Belgium, Spain, Austria, Luxembourg, and Italy (IVDR), the UK (MDR2002) and Switzerland (IvDO) with plans to expand into additional European countries and further milestones are scheduled for 2026.